National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).


NCPE Assessment Process Ongoing
Rapid review commissioned 28/11/2018
Rapid review completed 11/12/2018
Rapid Review outcome Full pharmacoeconomic assessment is recommended
HTA commissioned by the HSE 19/12/2019
Pre-submission consultation with Applicant 28/01/2019
Submission received from Applicant 01/04/2019
HTA assessment commenced 17/07/2019
Current Status HTA assessment ongoing